Viale G. (2012) The current state of breast cancer classification. Annals of oncology: official journal of the European Society for Medical Oncology 23 suppl 10:x207–210. https://doi.org/10.1093/annonc/mds326.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast Cancer Study. JAMA. 2006;295(21):2492–502. https://doi.org/10.1001/jama.295.21.2492.

Article  CAS  PubMed  Google Scholar 

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast Cancer 2011. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304.

Article  CAS  PubMed  Google Scholar 

Al-Thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg (Lond). 2020;49:44–8. https://doi.org/10.1016/j.amsu.2019.11.021.

Article  PubMed  Google Scholar 

Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Annals of Translational Medicine. 2020;8(7):499. https://doi.org/10.21037/atm.2020.03.194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol. 2013;230(2):228–38. https://doi.org/10.1002/path.4181.

Article  CAS  PubMed  Google Scholar 

Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M, Dell’Era P. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther. 2010;9(12):3244–53. https://doi.org/10.1158/1535-7163.MCT-10-0417.

Article  CAS  PubMed  Google Scholar 

Rodrigues PF, Matarazzo S, Maccarinelli F, Foglio E, Giacomini A, Silva Nunes JP, Presta M, Dias AAM, Ronca R. Long pentraxin 3-Mediated fibroblast growth factor trapping impairs Fibrosarcoma Growth. Front Oncol. 2018;8:472. https://doi.org/10.3389/fonc.2018.00472.

Article  PubMed  PubMed Central  Google Scholar 

Giacomini A, Ghedini GC, Presta M, Ronca R. Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta. 2018;1869(1):53–63. https://doi.org/10.1016/j.bbcan.2017.11.004.

Article  CAS  Google Scholar 

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C, Mantovani A. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015;160(4):700–14. https://doi.org/10.1016/j.cell.2015.01.004.

Article  CAS  PubMed  Google Scholar 

Presta M, Foglio E, Churruca Schuind A, Ronca R. Long Pentraxin-3 modulates the angiogenic activity of Fibroblast Growth Factor-2. Front Immunol. 2018;9:2327. https://doi.org/10.3389/fimmu.2018.02327.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M. (2013) Long Pentraxin-3 inhibits epithelial-mesenchymal transition in Melanoma cells. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.MCT-13-0487.

Matarazzo S, Melocchi L, Rezzola S, Grillo E, Maccarinelli F, Giacomini A, Turati M, Taranto S, Zammataro L, Cerasuolo M, Bugatti M, Vermi W, Presta M, Ronca R. Long Pentraxin-3 follows and modulates bladder Cancer Progression. Cancers. 2019;11(9). https://doi.org/10.3390/cancers11091277.

Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B, Mantovani A, Peri S, Friess HH, Post S, von Knebel Doeberitz M, Schwarzbach MH. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer. 2006;42(15):2639–46. https://doi.org/10.1016/j.ejca.2006.05.035.

Article  CAS  PubMed  Google Scholar 

Choi B, Lee EJ, Park YS, Kim SM, Kim EY, Song Y, Kang SW, Rhu MH, Chang EJ. Pentraxin-3 silencing suppresses gastric Cancer-related inflammation by inhibiting Chemotactic Migration of Macrophages. Anticancer Res. 2015;35(5):2663–8.

CAS  PubMed  Google Scholar 

Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, Tamura K, Okusaka T. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer. 2013;109(3):739–46. https://doi.org/10.1038/bjc.2013.348.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ying TH, Lee CH, Chiou HL, Yang SF, Lin CL, Hung CH, Tsai JP, Hsieh YH. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep. 2016;6:29385. https://doi.org/10.1038/srep29385.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locatelli M, Ferrero S, Martinelli Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, Bello L, Valentino S, Barbati E, Nebuloni M, Mantovani A, Garlanda C. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013;260(1–2):99–106. https://doi.org/10.1016/j.jneuroim.2013.04.009.

Article  CAS  PubMed  Google Scholar 

Scimeca M, Antonacci C, Colombo D, Bonfiglio R, Buonomo OC, Bonanno E. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(4):5427–35. https://doi.org/10.1007/s13277-015-4361-7.

Article  CAS  PubMed  Google Scholar 

Choi B, Lee EJ, Song DH, Yoon SC, Chung YH, Jang Y, Kim SM, Song Y, Kang SW, Yoon SY, Chang EJ. Elevated pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget. 2014;5(2):481–92. https://doi.org/10.18632/oncotarget.1664.

Article  PubMed  PubMed Central  Google Scholar 

Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal. 2017;10(467). https://doi.org/10.1126/scisignal.aah4674.

Zhang P, Liu Y, Lian C, Cao X, Wang Y, Li X, Cong M, Tian P, Zhang X, Wei G, Liu T, Hu G. SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation. Nat Commun. 2020;11(1):2487. https://doi.org/10.1038/s41467-020-16051-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed A, Redmond HP, Wang JH. Links between toll-like receptor 4 and breast cancer. Oncoimmunology. 2013;2(2):e22945. https://doi.org/10.4161/onci.22945.

Article  PubMed  PubMed Central  Google Scholar 

Wu K, Zhang H, Fu Y, Zhu Y, Kong L, Chen L, Zhao F, Yu L, Chen X. TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells. Mol Med Rep. 2018;18(3):3411–20. https://doi.org/10.3892/mmr.2018.9326.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casey AE, Laster WR Jr, Ross GL. Sustained enhanced growth of carcinoma EO771 in C57 black mice. Proc Soc Exp Biol Med. 1951;77(2):358–62. https://doi.org/10.3181/00379727-77-18779.

Article  CAS  PubMed  Google Scholar 

Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, Kumar T, Hu M, Sei E, Davis A, Wang F, Shaitelman SF, Wang JR, Chen K, Moulder S, Lai SY, Navin NE. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021;39(5):599–608. https://doi.org/10.1038/s41587-020-00795-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive Integration of single-cell data. Cell. 2019;177(7):1888–1902e1821. https://doi.org/10.1016/j.cell.2019.05.031.

Colucci-D’Amato L, Cicatiello AE, Reccia MG, Volpicelli F, Severino V, Russo R, Sandomenico A, Doti N, D’Esposito V, Formisano P, Chambery A. A targeted secretome profiling by multiplexed immunoassay revealed that secreted chemokine ligand 2 (MCP-1/CCL2) affects neural differentiation in mesencephalic neural progenitor cells. Proteomics. 2015;15(4):714–24. https://doi.org/10.1002/pmic.201400360.

Article  CAS  PubMed  Google Scholar 

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27. https://doi.org/10.1016/j.ccr.2006.10.008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS ONE. 2011;6(3):e17911. https://doi.org/10.1371/journal.pone.0017911.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jastrzebski K, Thijssen B, Kluin RJC, de Lint K, Majewski IJ, Beijersbergen RL, Wessels LFA. Integrative modeling identifies key determinants of inhibitor sensitivity in breast Cancer cell lines. Cancer Res. 2018;78(15):4396–410. https://doi.org/10.1158/0008-5472.CAN-17-2698.

Article  CAS  PubMed  Google Scholar 

Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011;71(5):1772–80. https://doi.org/10.1158/0008-5472.CAN-10-1735.

Article  CAS  PubMed  Google Scholar 

Chen B, Ye P, Chen Y, Liu T, Cha JH, Yan X, Yang WH. Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: elucidating Molecular Mechanisms and clinical significance. Front Oncol. 2020;10:1657. https://doi.org/10.3389/fonc.2020.01657.

Article  PubMed  PubMed Central